{"id":"76e5e9c4-7121-5026-a090-2f4770637980","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-longterm-lung-null","predicate":"does_not_significantly_increase","statement":"L+Z assignment had lung-cancer OR 1.15 (95% CI 0.79–1.66), without a significant increase.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"35b0bf34-2818-5b25-a37b-e97d04fd62db","mechanism_event_label":"The beta-carotene signal was not demonstrated for the pair.","subject":{"id":"23b4e9a5-0e3d-578b-aff7-100c6a8ac3e7","slug":"areds2-lz-addition","display_name":"AREDS2 lutein/zeaxanthin addition to background AREDS formulation","entity_type_key":"chemical_species"},"object":{"id":"330d7a68-255b-5e32-8a7f-8bdc06a889f8","slug":"human-lung-cancer-incidence","display_name":"Human lung cancer incidence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"35b0bf34-2818-5b25-a37b-e97d04fd62db","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-longterm-lung-null-event","event_type":"observed_intervention","label":"The beta-carotene signal was not demonstrated for the pair.","description":"L+Z assignment had lung-cancer OR 1.15 (95% CI 0.79–1.66), without a significant increase.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5dd84367-3f8e-5a3f-b952-a96174ea51fa","slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"0a60c685-7502-5ece-9da2-2c1a2e3bcdf1","slug":"zeaxanthin","display_name":"Dietary (3R,3-prime-R)-zeaxanthin","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"23b4e9a5-0e3d-578b-aff7-100c6a8ac3e7","slug":"areds2-lz-addition","display_name":"AREDS2 lutein/zeaxanthin addition to background AREDS formulation","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"330d7a68-255b-5e32-8a7f-8bdc06a889f8","slug":"human-lung-cancer-incidence","display_name":"Human lung cancer incidence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/lutein-research/35653117.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\", \"start_char\": 0, \"end_char\": 3155, \"text_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Ten-year epidemiologic follow-up of randomized AREDS2 assignments","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Original randomization followed by common AREDS2 supplementation for everyone","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not ten years of continuously separated randomized treatment; same cohort, additional follow-up.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Lutein research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"3882 original participants","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The beta-carotene signal was not demonstrated for the pair.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Late AMD and lung cancer","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ea799c1a-677b-5b1f-825f-9c7bdda974c2","evidence_kind":"source_excerpt","locator":"Lines 801-812","start_line":801,"end_line":812,"excerpt":"### lutein-areds-longterm-lung-null\nL+Z assignment had lung-cancer OR 1.15 (95% CI 0.79–1.66), without a significant increase.\nCondition category: normal\nnutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The beta-carotene signal was not demonstrated for the pair.\norganism: 3882 original participants\ntissue_or_cell_type: Late AMD and lung cancer\nexperimental_model: Ten-year epidemiologic follow-up of randomized AREDS2 assignments\nlimitations: Not ten years of continuously separated randomized treatment; same cohort, additional follow-up.\nexposure: Original randomization followed by common AREDS2 supplementation for everyone\nevidence_span: {\"source_cache\": \"artifacts/lutein-research/35653117.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\", \"start_char\": 0, \"end_char\": 3155, \"text_sha256\": \"66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb\"}\n[lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640","model_system":"Ten-year epidemiologic follow-up of randomized AREDS2 assignments","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"beef4241-6ebd-5b36-864c-6ef3ed7e61b8","stable_key":"import-cfa4bd86-d88d-555a-975c-68877bf00e0f","title":"Lutein: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"1514ec459913a7044b4c4e1012ed367bcb918298181ebabd2a9e2ccecd789053","revision_id":"bae2c856-0785-546f-b08f-869318c27f9e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}